Comparative Efficacy of Amlodipine Alone Versus Amlodipine Combined with Valsartan in Patients with Coronary Heart Disease and Hypertension.

BACKGROUND

Coronary heart disease (CHD) coupled with hypertension presents a significant health challenge worldwide. Optimal management strategies for controlling blood pressure and improving outcomes in this patient population remain a topic of interest and investigation within the medical community.

OBJECTIVE

This study aimed to compare the efficacy of amlodipine alone versus amlodipine combined with valsartan in patients diagnosed with coronary heart disease and hypertension.

METHODS

A prospective cohort study was conducted, and a total of 80 patients diagnosed with coronary heart disease and hypertension who visited the hospital between August 2022 and May 2024 were selected as study participants. Patients were allocated into two groups based on admission order: the control group (n=40) received amlodipine treatment, while the research group (n=40) received combined therapy with valsartan and amlodipine. The clinical efficacy between the two groups was compared.

RESULTS

Patients in the research group exhibited significantly better blood pressure control compared to the control group (P < .05). Moreover, the overall treatment effectiveness was notably higher in the research group than in the control group (P < .05). After treatment, a statistically significant difference was observed in blood lipid levels between the two patient groups (P <v .05). Similarly, post-treatment heart rate levels also displayed a significant difference between the two groups (P < .05).

CONCLUSION

Combining valsartan with amlodipine for patients presenting with coronary artery disease and hypertension significantly improves blood pressure management and enhances therapeutic outcomes. This finding emphasizes the clinical significance and potential widespread application of this combined treatment regimen.